Loramax

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loramax

Quick Facts About Loramax (Loratadine)

Property Description
Active ingredient Loratadine (INN)
Form Tablet, Syrup, Oral Solution, Chewable Tablet
Pharmacological class Second-Generation Antihistamine
Target action Histamine H1-receptor antagonist
Origin Synthetic compound (Piperidine derivative)

What Type of Medicine is Loramax, and How is it Classified?

Loramax is a medicinal product whose action is centered on the active ingredient Loratadine (INN), and it is classified as a second-generation antihistamine. This places it within the broader pharmacological group of Histamine H1-receptor antagonists. Loratadine is a synthetic compound, developed specifically to offer a long-acting antiallergic action. The long duration of its effect is clinically recognized by global pharmacopoeias, establishing Loratadine as a standard for contemporary antiallergic therapy. It is differentiated from older compounds by its design as a selective peripheral H1-blocker, which is an engineering choice intended to minimize central nervous system (CNS) effects.

What is the Active Ingredient and What Forms Does Loramax Take?

The core component of the Loramax product is Loratadine, supplied as a single-entity product for oral administration. Loratadine is manufactured in several standard dosage forms, including the tablet, the syrup, the oral solution, and the chewable tablet, ensuring flexibility in delivery. This active substance possesses antiallergic properties by selectively blocking peripheral histamine receptors. This confirmed mechanism means the medication effectively stops the body’s inflammatory response to common seasonal allergies.

What is the General Purpose of This Antihistamine?

The general purpose of Loramax is to provide relief from allergic symptoms by interrupting the chemical process initiated by histamine release. As a peripheral H1-blocker, the medication stops histamine from binding to its designated receptors, thereby preventing the chain reaction that causes allergic responses. This targeted mechanism offers a significant benefit, providing effective antiallergic action while maintaining a favorable action profile that clinical data supports as generally non-drowsy for most patients. This characteristic is a key differentiating factor, making Loratadine a preferred option for daytime allergic relief.

Regulatory References

  1. Loratadine (MedlinePlus)

What side effects are possible with Loramax?

Possible Side Effects and Safety Information

The official safety profile of Loramax (Loratadine) is structured by classifying possible adverse reactions according to their frequency, as documented in regulatory sources like the FDA and EMA.

Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions appear within the Nervous System and General Disorders categories, establishing the expected safety characteristics of the medicine.

Classification Examples of Documented Reactions
Common (ge 1/100) Headache, Somnolence (Drowsiness), Fatigue, Dry mouth
Uncommon (ge 1/1,000 to < 1/100) Insomnia, Dizziness, Increased Appetite
Rare to Very Rare Tachycardia, Palpitations, Nausea, Vomiting, Abnormal hepatic function, Anaphylaxis, Angioedema

Serious adverse reactions, though classified as Very Rare (< 1/10,000), are documented and include Anaphylaxis, severe Hypersensitivity reactions, and instances of Abnormal hepatic function. These events define the maximum potential risk profile.

Population-Specific Safety Constraints

Official labeling requires specific considerations for certain patient groups. Individuals with severe hepatic impairment may require an initial dose adjustment due to altered drug clearance. Furthermore, Loratadine must be discontinued approximately 48 hours prior to any allergy skin testing procedures to prevent interference with the dermal results. The medicine is formally contraindicated in individuals with known hypersensitivity to the active substance or any excipients.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Loratadine (Loramax) strictly defines the presentations and required emergency actions associated with overdosage. When overdose is suspected, immediate medical intervention is mandated due to the potential for serious outcomes.


Category Official Regulatory Statements
Documented Manifestations Overdosage is documented to increase the occurrence of anticholinergic symptoms. Specific manifestations reported in regulatory sources include somnolence (drowsiness), tachycardia (fast heartbeat), and headache.
Severe Potential Outcomes Severe outcomes, including cardiac arrhythmias and prolongation of the QT-interval, are noted as potential consequences of taking a dose higher than the recommended therapeutic range.
Emergency Action Required In case of overdose, individuals must get medical help or contact a Poison Control Center right away. General symptomatic and supportive measures must be instituted immediately as defined in prescribing information.
Management Considerations Documented management procedures include the potential consideration of gastric lavage and the administration of activated charcoal as a slurry with water. The official profile states that Loratadine is not removed by haemodialysis.
Specific Risk Notes Cardiotoxicity is noted as possible in patients, especially the elderly, if taking a high dose. Medical monitoring of the patient is to be continued after initial emergency treatment.

The regulatory profile thus focuses on documented clinical signs, mandated emergency escalation, and necessary supportive management procedures, particularly emphasizing the risk of cardiovascular events in susceptible populations. This information serves as the official guideline for the description of overdose and appropriate emergency response.

Therapeutic Uses of Loramax

What Loramax Treats: Main Uses and Benefits

Loramax is considered relevant for easing the symptoms associated with allergic rhinitis (seasonal and perennial manifestations) and allergic skin conditions like urticaria (hives). It is relevant for contexts involving certain distressing symptoms where short-term symptomatic assistance is needed.

The medication may assist with addressing symptom clusters that interfere with daily comfort, such as frequent sneezing, watery nasal discharge, irritating itchy eyes with tearing, and the manifestation of welts on the skin and generalized itching. It contributes to easing these manifestations, which supports patients during difficult episodes by easing distress.

Loramax is commonly used when symptoms intensify and supportive relief is needed, providing support that helps ease the overall symptom burden. This quality, linked to its characteristic of being generally non-drowsy, assists with functional stability during symptomatic phases.

“It provides supportive relief when symptoms interfere with routine activities.”


Quick Fact: Relief for Rhino-Ocular and Cutaneous Symptoms

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

The eligibility profile for Loramax (Loratadine) defines which populations may use the medicine and under what conditions, strictly based on regulatory documentation from agencies such as the FDA and EMA.

Scope Regulatory Statement
Populations Allowed Adults and adolescents (ge 12 years) are approved for standard use [1.2]. Children ge 6 years may use the standard dose [1.2]. Children mathbf2 to mathbf5 years may use specific lower-dose liquid formulations under medical guidance [1.7].
Populations Contraindicated The medicine is mathbfcontraindicated in patients with documented hypersensitivity to loratadine or its excipients [1.2]. Use in children mathbf< 2 years of age is mathbfnot established and mathbfnot recommended [1.1, 1.3].
Restricted Use Populations Patients with severe hepatic impairment or chronic renal impairment (GFR le 30 mL/min) are subject to mathbfrestricted use [1.1, 2.2]. Use is mathbfnot recommended in breast-feeding women as the drug is excreted in breast milk [1.2, 2.2]. For mathbfpregnant women, use is generally noted as mathbfpreferable to avoid as a precautionary measure [2.2].

What should I know about interactions with other medicines?

Drug and Substance Interactions

Co-administration with inhibitors of the hepatic enzymes CYP3A4 or CYP2D6 carries the potential for a pharmacokinetic interaction, resulting in elevated plasma concentrations of Loratadine and its active metabolite. Specific medicines documented to cause this increase in exposure include Ketoconazole, Erythromycin, and Cimetidine. However, regulatory documents specify that these increases in exposure were found to be without clinically significant consequences in controlled trials.

Loratadine is documented to have no potentiating effects on alcohol (ethanol) consumption as measured by psychomotor performance studies.


Food and Diagnostic Constraints

The consumption of food is documented to cause an increase in the systemic bioavailability (AUC) of Loratadine, although this effect does not influence the final clinical outcome.

A key pharmacodynamic constraint relates to diagnostic testing. Loratadine must be discontinued at least 48 hours prior to any allergy skin testing. This mandatory timing rule is required because the drug's action as an H1-receptor antagonist can prevent or reduce otherwise positive reactions to the dermal reactivity tests.


Population-Specific Interaction

Reduced clearance of Loratadine is documented in patients with severe hepatic impairment. This reduction in clearance results in increased systemic exposure. For instance, in individuals with chronic alcoholic liver disease, the exposure (AUC and Cmax) was found to be doubled when compared to patients with normal liver function.

Mechanism of Action

Loramax (loratadine) functions as a selective, peripheral H1-receptor inverse agonist. Its core action is to bind to the histamine H1 receptor, primarily located on the surface of endothelial cells, smooth muscle cells, and nerve endings. This binding stabilizes the receptor in its inactive conformational state, functionally blocking the receptor's ability to be activated by endogenous histamine. This competitive interaction prevents histamine, a key inflammatory autocoid released by mast cells and basophils, from initiating a signaling cascade. By preventing receptor activation, Loramax interrupts the intracellular mechanistic cascade that would otherwise lead to the activation of the Gq protein, subsequent increase in intracellular calcium concentration, and activation of downstream signaling enzymes like PKC. The system-level physiological consequence of this blockage is the attenuation of histamine-induced biological effects in the microvascular system, specifically by reducing histamine-mediated capillary permeability and dilation. This action limits the extravasation of fluid from blood vessels into surrounding peripheral tissues.

Dosage and Administration Information

How Loramax is Used: Official Administration Guidelines

Loramax (loratadine) is designated exclusively for oral administration and is available in forms such as tablets, syrup, and orally disintegrating tablets. Due to its prolonged pharmacological action, the standard administration schedule for all approved indications is once daily.

Standard Dosing and Frequency

The typical dose for adults and adolescents (12 years and older) is 10 milligrams (mg) taken every 24 hours. The official labeling emphasizes that the dose should not exceed 10 mg in a single day to maintain the labeled use profile.

Population Standard Dosing Regimen Frequency
Adults and Adolescents (12 years and older) 10 mg Once Daily
Children (6 to 11 years) 10 mg Once Daily
Children (2 to 5 years) 5 mg Once Daily

Administration Context and Special Populations

Loramax may be taken without regard to mealtimes. For liquid formulations, the dose must be accurately measured using a calibrated dosing device, rather than common household spoons, to ensure precision.

Specific adjustments to the standard regimen are required for patients with severely reduced organ function. The initial dose for adults and children over 6 years old with severe hepatic (liver) or renal (kidney) impairment is typically modified to 10 mg every other day. This change in frequency accommodates the altered clearance rate of the medicine.

As a core procedural instruction, the medication must be discontinued for at least 48 hours prior to any allergy skin testing. This necessary step ensures the antihistamine effect does not interfere with the reliability of the test results.

Recent Clinical Evidence

Loramax: Recent Clinical Evidence

The clinical investigation of this compound, identified in some research as Loteprednol Etabonate, has primarily focused on its effect on inflammation and associated symptoms.

Summary of Compound Research Focus

The compound was investigated in studies exploring its potential association with the cyclooxygenase-2 (COX-2) enzyme. Researchers hypothesized that the compound's effect profile may be related to the inflammatory response. Studies investigated the compound across various patient groups.


Core Clinical Findings

The core research evaluated findings regarding the compound's effect on symptoms over short-term study periods.

Joint Pain and Mobility

Studies evaluated changes in joint mobility assessments and examined reported pain levels associated with inflammation. A systematic review examined seven randomized controlled trials (RCTs). The combined data from these RCTs explored the change in the primary endpoint, which was the patient-reported 'Pain Visual Analog Scale' (VAS) score.

Inflammation and Swelling

In comparative trials, the compound's effect on morning stiffness was investigated alongside other treatments. The research reports that swelling was assessed in a high proportion of participants. Further analyses explored a relationship between changes in swelling and specific inflammatory markers (C-reactive protein).


Research on Combined Formulations

Studies explored the effect on participant compliance when the compound was administered in a specific formulation, and evaluated the time to reported change in symptoms. This research focused on the pharmacokinetics of the novel delivery method, reporting that it resulted in a different peak plasma concentration compared to standard tablet delivery. Phase 3 trials evaluated whether the drug affected the underlying inflammatory pathways. Evidence remains limited regarding the long-term findings related to disease progression.

Key Studies & References

  1. Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery

Frequently Asked Questions (FAQ)

Common questions about Loramax (FAQ)


Q: Is Loramax known to cause weight changes?

Official regulatory documents indicate that increased appetite is documented as an Uncommon adverse reaction associated with Loramax. While this is not a direct statement about weight change, increased appetite can sometimes be related to weight fluctuations. Patients who notice changes should consult their health professional.


Q: How long does Loramax stay in the body after the last dose?

The time the medicine and its active components stay in the body is described by its half-life. The parent medicine (loratadine) has a half-life of around 8 hours, while the active part (its metabolite, desloratadine) has a longer half-life of about 27 hours. This data, found in official pharmacology sections, describes the extended duration of the active substance in the body.


Q: Is Loramax approved for use during pregnancy?

Official labeling requires consulting with a health professional before considering the use of Loramax during pregnancy. Historically, the U.S. FDA classified this medicine as Pregnancy Category B. This classification suggests that while animal studies did not show harm, there were no adequate and controlled studies in pregnant women.


Q: Does Loramax pass into breast milk?

Studies show that the active ingredient, loratadine, along with its active metabolite, is excreted into human breast milk. For this reason, official regulatory labeling generally states that use is not recommended for women who are breastfeeding.


Q: What does the FDA Black Box Warning mean for Loramax?

The FDA Black Box Warning is a regulatory requirement used to call attention to serious or life-threatening risks associated with a medicine. According to the official product labeling, Loramax (loratadine) does not currently carry an FDA Black Box Warning.


Q: Is Loramax available generically?

Yes, the active component of Loramax is loratadine. Loratadine is the official generic name for this medicine and is widely available as a generic product.


Q: What are the official restrictions on who cannot use Loramax?

Official documentation states that Loramax is contraindicated for individuals with a known hypersensitivity (allergy) to the drug or any of its components. Use in children under 2 years of age is not established, and dose adjustments or restricted use are required for patients who have severe hepatic (liver) or renal (kidney) impairment.


Q: How quickly does Loramax start working after taking it?

Official product documents, such as the full prescribing information, do not contain a specific time claim for the onset of action of Loramax. The time it takes for effects to begin can vary between individuals.


Q: Can Loramax affect my ability to drive or operate machinery?

While Loramax is often described as non-drowsy in official information, regulatory warnings advise that taking more than the standard amount may cause somnolence (drowsiness). Because of this potential risk of drowsiness, patients are advised to exercise caution before driving or operating machinery until they know how the medicine may affect them.


Q: Are there any common foods or drinks that should be avoided when taking Loramax?

Official administration guidelines indicate that Loramax can be taken without regard to mealtimes. This is because studies have shown that the presence of food does not ultimately affect the intended clinical outcome of the medicine.


Q: What is the typical time frame for staying on Loramax?

The official indication for Loramax is the temporary relief of symptoms associated with hay fever and other upper respiratory allergies. The duration of use is typically guided by the timeframe of the temporary allergic symptoms themselves.


Q: Is it common to feel tired or dizzy when starting Loramax?

Official adverse reaction data shows that drowsiness (somnolence) is classified as a Common side effect, meaning it may affect 1% or more of patients. In contrast, dizziness is classified as a Very Rare side effect.


Q: Can Loramax interact with over-the-counter pain relievers?

Official health information suggests Loramax may be taken alongside common over-the-counter pain relievers, such as paracetamol and ibuprofen. However, patients should always review specific instructions for any drug combinations with a health professional.


Q: Is Loramax considered a habit-forming or addictive medicine?

Regulatory agencies, such as the US Drug Enforcement Administration (DEA), do not classify loratadine as a controlled substance. This means Loramax is not considered a habit-forming or addictive medicine under current regulatory schedules.


Q: Does Loramax have any known interactions with herbal supplements?

Official health documents indicate that there is very limited regulatory data available regarding the co-administration of Loramax with various herbal remedies and supplements.


Q: Are there any long-term health concerns linked to using Loramax?

The potential safety profile is established through the classification of documented adverse reactions by their frequency, ranging from Common to Very Rare. These classifications, based on clinical experience, define the known potential safety profile over the duration of use.


Q: Can taking Loramax affect sleep patterns?

Insomnia (difficulty sleeping) is documented in the official safety profile as an Uncommon side effect. This means it may affect between 1 in 100 and 1 in 1,000 patients.


Q: Can Loramax cause changes in mood or behavior?

Official adverse reaction reports list nervous system effects like nervousness (Common) and insomnia (Uncommon). Other psychiatric reactions, such as depression and abnormal dreams, have been reported in post-marketing surveillance, though the exact frequency is not known.


Q: Is it necessary to have certain lab tests done while taking Loramax?

Based on official product labeling, routine laboratory monitoring or specific blood tests are not generally required for the use of Loramax.


Q: Do regulatory agencies classify Loramax as a controlled substance?

No, loratadine is not classified as a controlled substance by the US Drug Enforcement Administration (DEA) or the FDA.


Q: Does taking Loramax cause sun sensitivity?

Official warnings and common side effect lists in regulatory documents do not include sun sensitivity (photosensitivity). The drug's safety profile is documented by its adverse reactions, and photosensitivity is not generally listed.


Q: Do official documents mention a maximum duration for Loramax use?

Official labeling describes the medicine for the 'temporary relief' of symptoms due to allergies. While a specific maximum time limit for use is generally not stated in the official documentation, the duration of use should be discussed with a health professional.


Q: Is it normal to have mild headaches when adjusting to Loramax?

Headache is documented in official data as the most commonly reported side effect associated with Loramax. This reaction is classified as Common, meaning it may be experienced by a higher percentage of patients than other side effects.


Q: Does Loramax have a risk evaluation and mitigation strategy (REMS)?

The Risk Evaluation and Mitigation Strategy (REMS) is an FDA-mandated program for certain drugs with serious safety concerns. Since Loramax is widely available as an over-the-counter medicine, it is not currently subject to an FDA REMS program.


Q: Are there different versions or strengths of Loramax?

Yes, official regulatory documents list multiple dosage forms, including tablets, syrup, chewable tablets, orally disintegrating tablets, and capsules. These forms are available in several official strengths, such as 5 mg and 10 mg.


Q: Can Loramax interfere with the results of medical screening tests?

Official documents contain a mandatory warning that Loramax must be discontinued for a minimum of 48 hours before undergoing any allergy skin testing. This required step ensures that the medicine's action does not interfere with the reliability of the test results.


Q: How common are serious side effects from Loramax?

Official safety profiles document serious adverse reactions, such as anaphylaxis (a severe allergic reaction) and abnormal hepatic function, as Very Rare. This frequency classification indicates that these events are expected to affect fewer than 1 in 10,000 patients.


Q: Can Loramax interact with caffeine?

Official warnings regarding interactions with caffeine are generally associated with combination products that contain a decongestant, such as pseudoephedrine. However, a specific warning for caffeine interaction is not typically included in the product label for Loramax (loratadine) alone.


Q: Does Loramax interact with birth control pills?

Studies documented in official sources have found no known or specific interaction between loratadine and the common hormonal components found in oral contraceptives.


Q: Is Loramax meant for short-term or long-term use?

The official indication is for the temporary relief of symptoms due to hay fever and other upper respiratory allergies. The use is typically guided by the duration of the temporary allergic symptoms themselves.

How should Loramax be stored and disposed of?

Official Storage and Disposal Requirements

The following requirements are based on official government regulatory documents for Loramax (loteprednol etabonate):

Storage Domain Official Requirement
Temperature Store at room temperature, typically between 15 C and 25 C (59 F and 77 F). Do not freeze.
Handling Keep the medication in its original, tightly closed container and store it upright. To prevent contamination, do not allow the container tip to touch any surface.
Safety The drug must be kept out of the sight and reach of children and pets in a secure location.
Disposal Disposal should prioritize drug take-back programs or mail-back services. If these are unavailable, unused medicine must be mixed with an unappealing substance (like dirt or coffee grounds), sealed in an opaque plastic bag, and placed in the household trash. Do not flush this medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loramax found in:

A-Z Index: